{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:33:04Z","timestamp":1793748784016,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002714","name":"Albert-Ludwigs-Universit\u00e4t Freiburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002714","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1160"],"award-info":[{"award-number":["SFB1160"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KI1795\/2-1"],"award-info":[{"award-number":["KI1795\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["441891347"],"award-info":[{"award-number":["441891347"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB-1479"],"award-info":[{"award-number":["SFB-1479"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011960","name":"DEBRA International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011960","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.eclinm.2024.102900","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T04:17:54Z","timestamp":1730348274000},"page":"102900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1\/2 trial"],"prefix":"10.1016","volume":"77","author":[{"given":"Dimitra","family":"Kiritsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Schauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Gewert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Reineker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Reimer-Taschenbrecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Schwieger-Briel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1792-3947","authenticated-orcid":false,"given":"Hagen","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Schmoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Grishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedee","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7657-4647","authenticated-orcid":false,"given":"Brigitte","family":"Stiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1306-1879","authenticated-orcid":false,"given":"Tobias","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4666-2240","authenticated-orcid":false,"given":"Alexander","family":"Nystr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Bruckner-Tuderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.eclinm.2024.102900_bib1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bjd.18921","article-title":"u. a. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility","volume":"183","author":"Has","year":"2020","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102900_bib2","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.15252\/emmm.201505061","article-title":"Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms","volume":"7","author":"Nystr\u00f6m","year":"2015","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102900_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","article-title":"u. a. Epidermolysis bullosa","volume":"6","author":"Bardhan","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.eclinm.2024.102900_bib4","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114392","article-title":"Pro-inflammatory immunity supports fibrosis advancement in epidermolysis bullosa: intervention with Ang-(1-7)","volume":"13","author":"Bernasconi","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102900_bib5","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jid.2020.10.024","article-title":"Diversity of mechanisms underlying latent TGF-\u03b2 activation in recessive dystrophic epidermolysis bullosa","volume":"141","author":"Akasaka","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102900_bib6","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/exd.14154","article-title":"The renin-angiotensin system in cutaneous hypertrophic scar and keloid formation","volume":"29","author":"Hedayatyanfard","year":"2020","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.eclinm.2024.102900_bib7","series-title":"Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist","article-title":"A\u00a0formulation for preparing losartan potassium 2.5-mg\/mL oral liquid","author":"Allen Loyd","year":"2007"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102900_bib8","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/bjd.18475","article-title":"Natural history of growth and anaemia in children with epidermolysis bullosa: a retrospective cohort study\u2217","volume":"182","author":"Reimer","year":"2020","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102900_bib9","first-page":"20","article-title":"The natural history of severe recessive dystrophic epidermolysis bullosa \u2013 4 phases which may help determine different therapeutic approaches","volume":"2","author":"Bageta","year":"2021","journal-title":"J\u00a0Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102900_bib10","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1365-2133.2009.09041.x","article-title":"The Birmingham epidermolysis bullosa severity score: development and validation","volume":"160","author":"Moss","year":"2009","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102900_bib11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/jdv.13953","article-title":"The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa","volume":"31","author":"Jain","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102900_bib12","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1365-2133.2009.09347.x","article-title":"Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument","volume":"161","author":"Frew","year":"2009","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102900_bib13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2133.2003.05157.x","article-title":"The Children's Dermatology life quality index: validation of the cartoon version","volume":"148","author":"Holme","year":"2003","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102900_bib14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s13075-022-02943-2","article-title":"Periostin overexpression in scleroderma cardiac tissue and its utility as a marker for disease complications","volume":"24","author":"El-Adili","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102900_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jdermsci.2020.10.009","article-title":"Aberrant recruitment of leukocytes defines poor wound healing in patients with recessive dystrophic epidermolysis bullosa","volume":"100","author":"Phillips","year":"2020","journal-title":"J\u00a0Dermatol Sci"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102900_bib16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2796.2003.01071.x","article-title":"Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment","volume":"253","author":"Usta","year":"2003","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.eclinm.2024.102900_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112931","article-title":"Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-\u03b2\/Smad","volume":"149","author":"Zou","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"10355","key":"10.1016\/j.eclinm.2024.102900_bib18","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(22)01534-3","article-title":"Angiotensin receptor blockers and \u03b2 blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials","volume":"400","author":"Pitcher","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102900_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010059","article-title":"Comparative therapeutic strategies for preventing aortic rupture in a mouse model of vascular Ehlers-Danlos syndrome","volume":"18","author":"Legrand","year":"2022","journal-title":"PLoS Genet"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102900_bib20","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1093\/ndt\/gfq797","article-title":"Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial","volume":"26","author":"Webb","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.eclinm.2024.102900_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119578","article-title":"Effects of losartan and l-serine in a mouse liver fibrosis model","volume":"278","author":"Yun","year":"2021","journal-title":"Life Sci"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102900_bib22","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/wrr.12648","article-title":"Losartan ointment relieves hypertrophic scars and keloid: a pilot study","volume":"26","author":"Hedayatyanfard","year":"2018","journal-title":"Wound Repair Regen"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102900_bib23","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/bjd.18743","article-title":"Use of topical valsartan as a novel treatment for complicated leg ulcers","volume":"182","author":"Hirt","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.eclinm.2024.102900_bib24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jdin.2022.07.008","article-title":"Long-term follow-up of epidermolysis bullosa in real practice shows stability of the Epidermolysis Bullosa Disease Activity and Scarring Index and improvement with some off-label therapies","volume":"9","author":"Ho","year":"2022","journal-title":"JAAD Int"},{"key":"10.1016\/j.eclinm.2024.102900_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15678","article-title":"Losartan as therapy for recessive dystrophic epidermolysis bullosa: report of three cases","volume":"35","author":"Relvas","year":"2022","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102900_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14279","article-title":"Losartan as disease modulating therapy for recessive dystrophic epidermolysis bullosa","volume":"33","author":"Inamadar","year":"2020","journal-title":"Dermatol Ther"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102900_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15515","article-title":"Losartan treatment improves recessive dystrophic epidermolysis bullosa: a case series","volume":"35","author":"Pourani","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.eclinm.2024.102900_bib28","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa0910501","article-title":"Bone marrow transplantation for recessive dystrophic epidermolysis bullosa","volume":"363","author":"Wagner","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102900_bib29","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jaad.2013.08.014","article-title":"u. a. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa","volume":"69","author":"Venugopal","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102900_bib30","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/jid.2015.158","article-title":"Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa","volume":"135","author":"Petrof","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102900_bib31","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41591-022-01737-y","article-title":"In\u00a0vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial","volume":"28","author":"Gurevich","year":"2022","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.eclinm.2024.102900_bib32","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","article-title":"Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa","volume":"387","author":"Guide","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024004796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024004796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:04:17Z","timestamp":1778904257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024004796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":32,"alternative-id":["S2589537024004796"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102900","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1\/2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102900","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102900"}}